Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2018, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape.
Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 5, 5, 1, 1, 14, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Nausea and Vomiting - Overview
Chemotherapy Induced Nausea and Vomiting - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development
Acacia Pharma Ltd
Aphios Corp
Athenex Inc
Camurus AB
Daewoong Pharmaceutical Co Ltd
Hoverink Biotechnologies Inc
IntelGenx Corp
Kyowa Hakko Kirin Co Ltd
MannKind Corp
Medlab Clinical Ltd
N4 Pharma Plc
Nemus Bioscience Inc
Pivot Pharmaceuticals Inc
Serina Therapeutics Inc
SoluBest Ltd
Suda Pharmaceuticals Ltd
Chemotherapy Induced Nausea and Vomiting - Drug Profiles
(netupitant + palonosetron hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APD-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cannabis CINV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosnetupitant chloride hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
granisetron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
granisetron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
granisetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
granisetron hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPI-1504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPI-1505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1222 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-2111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-1940 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netupitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olanzapine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palonosetron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palonosetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVT-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SER-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize CB1 and CB2 for Chemotherapy Induced Nausea and Vomiting - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chemotherapy Induced Nausea and Vomiting - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Zindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chemotherapy Induced Nausea and Vomiting - Dormant Projects
Chemotherapy Induced Nausea and Vomiting - Discontinued Products
Chemotherapy Induced Nausea and Vomiting - Product Development Milestones
Featured News & Press Releases
Jul 09, 2018: Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO, a combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV)
Jul 03, 2018: Ministry approves CJ Healthcare’s CINV treatment
Jun 28, 2018: Helsinn Therapeutics (U.S.) becomes the Exclusive Distributor of ALOXI (palonosetron HCI) in the US
May 18, 2018: Helsinn Group and Mundipharma announce the launch of AKYNZEO hard capsule for oral use in Brazil
May 15, 2018: AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco
Apr 24, 2018: Helsinn Group to Present a Poster at Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018
Apr 20, 2018: Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO (fosnetupitant/palonosetron) in the United States
Jan 17, 2018: US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi in the US Market Are Invalid
Dec 22, 2017: N4 Pharma: Filing of Patent
Dec 12, 2017: AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND Submission
Nov 28, 2017: New single capsule treatment AKYNZEO now available for the prevention of chemotherapy-induced nausea and vomiting in Canada
Jun 20, 2017: Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC
May 15, 2017: AXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on NIH Website
May 03, 2017: Patent Infringement Litigation For Antiemetic Agent ALOXI In The United States
May 02, 2017: Helsinn Healthcare vs. Teva Pharmaceuticals on Aloxi patent for the US market
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corp, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Athenex Inc, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Camurus AB, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Hoverink Biotechnologies Inc, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by IntelGenx Corp, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by MannKind Corp, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Medlab Clinical Ltd, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by N4 Pharma Plc, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Nemus Bioscience Inc, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Pivot Pharmaceuticals Inc, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Serina Therapeutics Inc, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd, H2 2018
Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Pharmaceuticals Ltd, H2 2018
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H2 2018
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H2 2018 (Contd..1), H2 2018
Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018
